<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89019">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874652</url>
  </required_header>
  <id_info>
    <org_study_id>0007-13-BNZ</org_study_id>
    <nct_id>NCT01874652</nct_id>
  </id_info>
  <brief_title>Assessment of Safety &amp; Efficacy of Light Weight Breast Implant</brief_title>
  <official_title>Assessment of Safety &amp; Efficacy of Light Weight Breast Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and effectiveness of Light Weight Breast
      Implant (LWBI) in breast augmentation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Single-center.  The purpose of the study is to evaluate safety and effectiveness
      of LWBI in breast augmentation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>No reoperation during 6 months follow up period</measure>
    <time_frame>during 6 months follow up period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>•  duration for all adverse events (AEs) on per patient and per implant basis will be recorded and analyzed.</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Capsular Contracture of Breast Implant, Sequela</condition>
  <arm_group>
    <arm_group_label>Light Weight Breast Implants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of Safety and Efficacy of Light Weight Breast Implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Weight Breast Implants</intervention_name>
    <description>Light Weight Breast Implants</description>
    <arm_group_label>Light Weight Breast Implants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetic women at ages 22 to 65 seeking breast enlargement

          -  Signed informed consent

          -  Agreement to complete all required follow up visits

          -  A medically acceptable candidate

          -  Sufficient breast tissue for proper implant coverage (≥20 mm by pinch test)

        Exclusion Criteria:

          -  Patients with active infection anywhere in their body

          -  Women who are currently pregnant or nursing

          -  Insufficient tissue covering in the prospective area of implantation (e.g. after
             preceding breast reduction), radiation damage or reduced vascularization

          -  Abscesses, cysts or tumors in the area of implants, especially cancer and recurrent
             metastases (e.g. persistent or intermittent mammary cancer), advanced fibrocystic
             diseases

          -  Patients with a history of psychiatric treatment

          -  Expected allergies or extraordinary immune response to implants

          -  Wound healing impairments or heavy burn scars

          -  Existing costal injuries
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noam Calderon, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai-Zion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnai Zion</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
